News | Congenital Heart | October 03, 2022

Memorial Cardiac and Vascular Institute Battling Heart Disease in a New Place

The new ECHO lab enables cardiac teams to use ultrasound (or echocardiography) to assess the size and efficiency of heart chambers. Stress tests, coronary CTAs, and cardiac MRIs are also interpreted there. 

The new ECHO lab enables cardiac teams to use ultrasound (or echocardiography) to assess the size and efficiency of heart chambers. Stress tests, coronary CTAs, and cardiac MRIs are also interpreted there.

October 3, 2022 — A new ‘ECHO lab’ at Memorial Hospital West is benefiting patients that may have heart disease and the cardiac specialists that treat them. 

The space enables cardiac teams to use ultrasound (or echocardiography) to assess the size and efficiency of heart chambers. This non-invasive, outpatient test also allows for assessment of blood flow through the heart valves to determine if there is narrowing, backflow, or other issues that prevent optimal function. Stress tests, coronary CTAs, and cardiac MRIs are also interpreted there. “Our cardiac teams were involved in the design of the ECHO lab and were able to maximize use of the space,” said Dr. Omosalewa Adewale, medical director of cardiac imaging at Memorial Cardiac and Vascular Institute

Congenital heart disease, cardiomyopathy, infective endocarditis, pericardial disease, and rheumatic heart disease are just a few of the ailments that can be diagnosed through echocardiographic testing. It can also determine how other diseases, including cancer and stroke, have affected the heart’s function. 

Memorial’s cardiac sonographers, cardiology fellowship trainees, and cardiologists all collaborate to interpret imaging tests that influence treatment decisions. 

The Memorial Cardiac & Vascular Institute is a cardiovascular care leader, offering a wide array of services dedicated to the prevention, detection, and treatment of cardiovascular disease. Its multi-disciplinary specialists collaborate using sophisticated diagnostic equipment and facilities. Cardiovascular care outcomes are regularly reviewed by physician-review panels and nurses to ensure quality assurance that utilizes computerized data collection. 

For more information: mhs.net/services/cardiac-vascular 


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now